NEW!

Hypertension (HTN) remains a challenging medical problem, affecting an estimated 1.13 billion individuals worldwide. HTN is the major cause of cardiovascular-related mortality worldwide; cardiovascular death accounts for 31% of global death every year. In Malaysia, HTN was the biggest contributor to the main cause of mortality and disability-adjusted life years in 2018. Alarmingly, many individuals are unaware that they have HTN, and most of those with HTN do not have their blood pressure under control. As a result, suboptimal control puts a tremendous burden on the health and welfare of individuals and the population. This online CPD video provides an update on the evidence for managing HTN, while simultaneously highlighting the role of single-pill fixed-dose combination to promote adherence to HTN treatment.

Presenter:

Dr Alan Fong Yean Yip

Consultant Cardiologist

Sarawak Heart Centre

Kuching, Sarawak

• Lecture
• Q&A session

Who should participate:
• Doctors

Terms & Conditions:

·    Participants must obtain a minimum score of 8/10 (80%) to be awarded 1 point. 

·   MIMS Education and MIMS Medica shall not be responsible or liable for the outcome of your CPD points.

·    This educational message is brought to you by Pfizer.

For more information on HTN therapy, please visit:

http://www.mims.com/malaysia/drug/info/azoren/?type=full

http://www.mims.com/malaysia/drug/info/olmetec/?type=full

Please watch the video before attempting the assessment questions.

To play this video, you are required to have a media player such as Windows Media Player (PC), QuickTime (MAC) or another third party media player.